



## Supporting Information

### Enhanced Antimicrobial Protection through Surface Immobilization of Antibiotic-Loaded Peptide Multicompartment Micelles


Shabnam Tarvirdipour<sup>a,b</sup>, S. Narjes Abdollahi<sup>a</sup>, Joachim Köser<sup>c</sup>, Maryame Bina<sup>a</sup>, Cora-Ann Schoenenberger<sup>a</sup>,  
Cornelia G. Palivan<sup>a,b\*</sup>



**Fig. S1.** A) CryoTEM image of RIF-MCMs, scale bar = 100 nm. B) Negatively stained TEM overview, C) DLS size distribution, and D) Zeta potential of unloaded MCMs, scale bar = 200 nm.




**Fig. S2.** (A) Size distribution and (B) zeta potential distribution of RIF-MCMs formed at different mass ratios of rifampicin to peptide (1:4, 1:2, and 1:1 RIF:peptide).




**Fig. S3.** Standard curve of free RIF in dimethyl sulfoxide (DMSO).

**Table S1.** Concentration of RIF-MCMs determined by NTA and calculated encapsulation efficiencies (EEs).


RIF-loaded MCMs	Concentration (particles/mL)*10 <sup>9</sup>	EE (%)
1:4 RIF:Pep	12.6 ± 0.9	46
1:2 RIF:Pep	9.8 ± 1.6	84
1:1 RIF:Pep	4.4 ± 0.6	67




**Fig. S4.** FTIR spectra of RIF, MCMs and RIF-MCMs (1:2 RIF:Pep).



**Fig. S5.** Standard curve of free RIF in HEPES buffer (25 mM HEPES, pH 7.4, containing 150 mM NaCl and 0.5% ascorbic acid).




**Fig. S6.** QCM-D profiles for the deposition of free peptide, followed by a washing step with water at room temperature. The frequency variations were recorded for the 3<sup>rd</sup>, 5<sup>th</sup>, 7<sup>th</sup>, and 9<sup>th</sup> harmonics. The right panel displays the frequency shifts associated with the binding of free peptide to the solid support, before and after the washing step.




**Fig. S7.** AFM topography of bare glass substrate (Ai-iii), and unloaded MCMs (Bi-iii) and RIF-MCMs (Ci-iii) immobilized on a glass surface. For each sample, three randomly selected areas were recorded.






**Fig. S8.** CLSM micrographs of *Bacillus subtilis*-incubated surfaces. Substrates were immersed in a bacterial suspension ( $10^7$  CFU mL<sup>-1</sup>) and incubated for 4 h at 37 °C. Bacteria were stained with Syto 9 (green, live cells) and PI (red, dead cells). Scale bar = 50  $\mu$ m.



**Fig. S9.** Image of agar plates showing a dilution series of *S. aureus* bacteria retrieved from: (A) untreated, (B) MCM-modified, and (C) RIF-MCM modified surfaces using antimicrobial assays in accordance with ISO 22196 standards. For untreated and MCM-modified surfaces, 10  $\mu$ l aliquots were plated in triplicates for each dilution, with the highest dilution displayed on the left side of each plate. For RIF-MCM-modified surfaces, single 100  $\mu$ l aliquots were plated.



**Fig. S10.** Effect of MCMs and RIF on human cell viability. The proliferation of A549 cells after 48 h of treatment with Dose I, Dose II, and Dose III at 37 °C was assessed using MTS assays. For RIF-MCMs, dose I corresponds to the concentration applied for full surface coverage with RIF-MCMs, dose II is double this concentration, and dose III triple. For unloaded MCMs, doses I to III have peptide concentrations equivalent to those used for RIF-MCM treatment. Doses I, II and III of free RIF correspond to the amount of RIF entrapped in the respective doses of RIF-MCMs. Control cells were incubated correspondingly but without treatment. Error bars represent standard deviation of triplicate measurements.